CHANNEL BY TOPICS

QUICK LINKS

Natera Appoints Herm Rosenman as Chief Financial Officer

SAN CARLOS, Calif. --(Business Wire)--

Natera Inc., a leading innovator in prenatal genetic testing, today
announced the appointment of Herman "Herm" Rosenman to the position of
chief financial officer. Mr. Rosenman has served as a member of the
company's board of directors since 2013 and brings more than 30 years of
public company operating and financial experience to Natera. He will
join the company on Feb. 10, 2014.

Mr. Rosenman was most recently the senior vice president of finance and
chief financial officer of Gen-Probe Inc., where he was instrumental in
its September 2002 IPO and its August 2012 sale to Hologic Inc. for $3.7
billion. Prior to joining Gen-Probe, he was president and chief
executive officer of Ultra Acquisition Corp., a retail chain and
consumer products manufacturer, and president and chief executive
officer of RadNet Management Inc., a large healthcare provider. At
RadNet, he developed and implemented strategies that resulted in the
company's successful turnaround. Before this, he was the chief financial
officer of Rexene Corp., a Fortune 1000 company in the petrochemicals
industry, where he led its successful $150 million IPO and $500 million
debt financing. Prior to Rexene, Mr. Rosenman was a partner at Coopers &
Lybrand (now PricewaterhouseCoopers (News - Alert) LLP), where he served numerous
Fortune 1000 clients, principally in the pharmaceuticals and
telecommunications indusries.

"This is a big win for Natera," said Matthew Rabinowitz, Ph.D., chief
executive officer of Natera. "Herm has been a member of our Board of
Directors and now will play a key role in the continued expansion of our
company."

Mr. Rosenman currently serves as chairman of the audit committees of
Oxford Immunotec Ltd., Medistem Inc. and VIVUS Inc., where he is also a
member of their compensation committees. In addition, he is a member of
the advisory board for Scripps Clinics/Green Hospital in San Diego. A
C.P.A., Mr. Rosenman received a B.B.A. in finance and accounting from
Pace University and an M.B.A. in finance from the Wharton School of the
University of Pennsylvania.

"I look forward to working as part of the Natera team to support the
company's continued growth and deliver the most accurate reproductive
genetic testing in the world," Mr. Rosenman said.

About Natera

Natera Inc. is a genetic testing company that specializes in analyzing
tiny quantities of DNA for reproductive health. Natera operates a
CLIA-certified laboratory in San Carlos, Calif., providing a host of
preconception and prenatal genetic testing services. Test offerings
include pre-implantation genetic diagnosis to identify chromosomal
anomalies or inherited genetic conditions in embryos generated during an
IVF cycle; products-of-conception testing following miscarriage to
analyze fetal chromosomes and understand the cause of the pregnancy
loss; non-invasive prenatal testing to determine paternity; carrier
screening to detect whether parents carry genetic variations that may
result in disease in the child; and Panorama, a safe, simple test for
pregnant women that identifies the most common chromosomal anomalies in
a fetus as early as nine weeks of gestation. Natera's PreNATUS clinical
trial for non-invasive screening of fetal chromosomal anomalies is
funded by the NIH and is being conducted by the leaders in
maternal-fetal medicine in the United States. These tests were developed
by Natera, a laboratory certified under the Clinical Laboratory
Improvement Amendments (CLIA). They have not been cleared or approved by
the U.S. Food and Drug Administration (FDA). In August, Natera was
selected by the World Economic Forum as a Technology Pioneer for
innovations in prenatal care. For more information, visit www.natera.com.